Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zivo Bioscience, Inc.ZIVO · Entity 9611 | Director · President / CEO | October 21, 2021 | October 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zivo Bioscience, Inc.
Report date October 21, 2021 · Filed October 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2031-10-20 | Direct | 376,000 |
Reported balance
After 2021-10-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-21 · Grant · Acquired 376,000 · Balance 376,000 F1: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 21, 2021 Filed Oct 25, 2021 23:07 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 376,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001654954-21-011339 · section16.xml · derivative · entry 1 DAHL ANDREW A · CIK 0001537603 · Director · President / CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,000 Underlying: Common Stock · 376,000 shares Expires 2031-10-20 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant. Read SEC document |
| September 11, 2020 Filed Feb 17, 2021 01:54 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GiftCommon Stock Purchase Warrant · Derivative | 4,000,000 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0001078782-21-000141 · primary_doc.xml · derivative · entry 1 DAHL ANDREW A · CIK 0001537603 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000,000 Underlying: Common Stock · 4,000,000 shares Expires 2022-11-08 F1 · price: The warrants were issued to the reporting person as compensation for his services as President and CEO. Read SEC document |
| December 06, 2019 Filed Apr 8, 2020 20:04 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Option · Derivative | 1,000,000 | Not disclosed Strike: $0.14 | Not disclosed |
DisclosureSEC source: 0001078782-20-000242 · primary_doc.xml · derivative · entry 2 DAHL ANDREW A · CIK 0001537603 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2029-12-06 F1 · price: The warrants were issued to the reporting person as compensation for his services as President and CEO. Read SEC document |
| November 15, 2019 Filed Apr 8, 2020 20:04 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Option · Derivative | 28,000,000 | Not disclosed Strike: $0.10 | Not disclosed |
DisclosureSEC source: 0001078782-20-000242 · primary_doc.xml · derivative · entry 1 DAHL ANDREW A · CIK 0001537603 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000,000 Underlying: Common Stock · 28,000,000 shares Expires 2029-11-15 F1 · price: The warrants were issued to the reporting person as compensation for his services as President and CEO. Read SEC document |
| November 08, 2017 Filed Feb 9, 2018 21:22 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantCommon Stock Purchase Warrant · Derivative | 10,000,000 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0001078782-18-000112 · primary_doc.xml · derivative · entry 1 DAHL ANDREW A · CIK 0001537603 · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000,000 Underlying: Common Stock · 10,000,000 shares Expires 2022-11-08 F1 · price: The warrants were issued to the reporting person as compensation for his services as President and CEO. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.